Pulmonary Cell News Volume 3.39 | Oct 9 2014

Extracellular Signal-Regulated Kinase Pathway Play Distinct Role in Acetochlor-Mediated Toxicity and Intrinsic Apoptosis in A549 Cells
Researchers elucidated the effect and molecular mechanisms of acetochlor (ACETO) on human alveolar A549 cells. Established assays of cell viability and cytotoxicity were performed to detect the potential effects of ACETO on A549 cells. [Toxicol In Vitro] Abstract

Non-Specific Interaction of Carbon Nanotubes with the Resazurin Assay Reagent: Impact on In Vitro Assessment of Nanoparticle Cytotoxicity
Nanomaterials (NMs), in particular carbon nanotubes can interfere in assays through quenching of transmitted light or fluorescence. Scientists show that using the resazurin assay with time-point reading of clarified supernatants resolves this problem. Human lung epithelial and murine macrophage cell lines were exposed to NMs in 96-well plates in 200 μL of media/well. [Toxicol In Vitro] Full Article

Systematic Identification of Transcriptional and Post-Transcriptional Regulations in Human Respiratory Epithelial Cells during Influenza A Virus Infection
The molecular mechanisms of airway epithelial cell responses to viral infection are not fully understood. Researchers propose a novel framework named SITPR to investigate the interactions among transcription factors, microRNAs and target genes. [BMC Bioinformatics] Abstract | Full Article

LUNG CANCER

Differential Roles of STAT3 in the Initiation and Growth of Lung Cancer
Scientists demonstrate that STAT3 has contrasting roles in the initiation and growth of both chemically and genetically induced lung cancers. Deletion of lung epithelial STAT3 after establishment of lung cancer inhibited cancer cell proliferation. [Oncogene] Abstract

Reduced miR-3127-5p Expression Promotes NSCLC Proliferation/Invasion and Contributes to Dasatinib Sensitivity via the c-Abl/Ras/ERK Pathway
Overexpression of miR-3127-5p significantly reduced non-small-cell lung cancer (NSCLC) cells proliferation, migration, and motility in vitro and in vivo. [Sci Rep] Full Article

The Expression of p21 Is Upregulated by Forkhead Box A1/2 in p53-Null H1299 Cells
Scientists demonstrate that forkhead box A1/2 is a crucial transcription factor in the activation of p21 transcription via direct binding to the p21 promoter in p53-null H1299 lung carcinoma cells. [FEBS Lett] Abstract

A Flavonoid Isolated from Streptomyces sp. (ERINLG-4) Induces Apoptosis in Human Lung Cancer A549 Cells through p53 and Cytochrome C Release Caspase Dependent Pathway
Cytotoxic properties of ethyl acetate extract was carried out against the A549 lung cancer cell line using the 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Cytotoxic properties of isolated compound were investigated in the A549 lung cancer cell line, COLO320DM cancer cell line and Vero cells. [Chem Biol Interact] Abstract

Expression of MicroRNA-96 and Its Potential Functions by Targeting FOXO3 in Non-Small Cell Lung Cancer
Quantitative reverse transcription PCR was performed to identify the microRNA (miR)-96 expression level in 68 paired non-small cell lung cancer and adjacent normal lung tissues. Trans-well, cell counting kit-8, and apoptosis assays were used to evaluate the effects of miR-96 expression on cell invasion, proliferation, and apoptosis. [Tumor Biol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated reviewed recent progress and announced upcoming milestones in its efforts to develop multiple combinations of medicines that treat the underlying cause of cystic fibrosis for the majority of people with the disease. [Press Release from Vertex Pharmaceuticals Incorporated discussing research presented at the 28^th Annual North American Cystic Fibrosis Conference (NACFC), Atlanta]
Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Savara Pharmaceuticals Raises $10 Million to Advance AeroVanc for MRSA Lung Infection in People with Cystic Fibrosis
Savara Pharmaceuticals announced that it closed a $10 million bridge financing round to support the development of AeroVanc, the first inhaled antibiotic being developed to address the growing number of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis. [Savara Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

PhD Position – Development of a Lung-on-a-Chip (University of Twente)

Postdoctoral Fellow – Experimental Pulmonary Hypertension (Brigham and Women’s Hospital Harvard Medical School)

Investigator – Multiple Positions in Cellular & Molecular Medicine (Cleveland Clinic Lerner Research Institute)

PhD Studentship – Pediatric Respiratory Epidemiology (University of Bern)

Postdoctoral Fellow – Cardiopulmonary Molecular Biology (Hannover Medical School)

Postdoctoral Position – Pulmonary Research (University of Chicago)

Postdoctoral Researcher – Cancer (Ohio State University)

Postdoctoral Research Trainee – Acute Lung Injury (University of Tennessee Health Science Center)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.